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Background: Dyslipidaemia and dysglycaemia have been associated with exposure to ritonavir-boosted protease
inhibitors. Lopinavir/ritonavir, the most commonly used protease inhibitor in resource-limited settings, often causes
dyslipidaemia. There are contradictory data regarding the association between lopinavir concentrations and
changes in lipids.
Aim: To investigate associations between plasma lopinavir concentrations and lipid and glucose concentrations in
HIV-infected South African adults.
Methods: Participants stable on lopinavir-based antiretroviral therapy were enrolled into a cross-sectional study.
After an overnight fast, total cholesterol, triglycerides, and lopinavir concentrations were measured and an oral
glucose tolerance test was performed. Regression analyses were used to determine associations between plasma
lopinavir concentrations and fasting and 2 hour plasma glucose, fasting cholesterol, and triglycerides
concentrations.
Results: There were 84 participants (72 women) with a median age of 36 years. The median blood pressure, body
mass index and waist: hip ratio were 108/72 mmHg, 26 kg/m2 and 0.89 respectively. The median CD4 count was
478 cells/mm3. Median duration on lopinavir was 18.5 months. The median (interquartile range) lopinavir
concentration was 8.0 (5.2 to 12.8) μg/mL. Regression analyses showed no significant association between
lopinavir pre-dose concentrations and fasting cholesterol (β-coefficient −0.04 (95% CI −0.07 to 0.00)), triglycerides
(β-coefficient −0.01 (95% CI −0.04 to 0.02)), fasting glucose (β-coefficient −0.01 (95% CI −0.04 to 0.02)), or 2-hour
glucose concentrations (β-coefficient −0.02 (95% CI −0.09 to 0.06)). Lopinavir concentrations above the median
were not associated with presence of dyslipidaemia or dysglycaemia.
Conclusions: There was no association between lopinavir plasma concentrations and plasma lipid and glucose
concentrations.
Keywords: Lopinavir, Hypercholesterolaemia, Hypertriglyceridaemia, Impaired glucose metabolism, Antiretroviral
therapy, PharmacokineticsIntroduction
Ritonavir-boosted lopinavir (LPV/r) is a potent protease
inhibitor (PI) widely used in a second-line antiretroviral
regimens in low and middle-income countries [1]. Treat-
ment with LPV/r has been associated with the develop-
ment of dyslipidaemia [2,3], which is a known risk factor* Correspondence: phumla.sinxadi@uct.ac.za
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reproduction in any medium, provided the orfor cardiovascular complications. The Women’s Intera-
gency HIV study showed that dyslipidaemia was more
severe in HIV infected women on ritonavir-boosted PI
containing antiretroviral therapy (ART), compared with
untreated HIV infected women or non-PI based ART
[4]. There are conflicting results regarding an association
between LPV/r use and the development of insulin re-
sistance and new onset diabetes [5-9]. Furthermore,
there are contradictory data as to whether the metabolic
toxicity is associated with higher plasma concentrationsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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term PI use may be limited by these metabolic complica-
tions. Data regarding an association between plasma
lopinavir and plasma glucose concentration are lacking.
The aim of our study was to investigate whether there
is an association between plasma lopinavir and plasma
lipids and glucose concentrations. We hypothesized that
higher plasma lopinavir concentrations would be asso-
ciated with higher prevalence of dyslipidaemia and
dysglycaemia.
Materials and methods
Study design and participants
We conducted a prospective cross sectional study be-
tween February 2007 and January 2008. Consecutive am-
bulatory HIV infected African adults who presented for a
routine follow up visit at primary and tertiary level clinics
in Cape Town were recruited. Participants were eligible if
they were on lopinavir-based therapy for a minimum of
six months. Participants with renal or hepatic disease,
active opportunistic infection, diabetes, history of dia-
betes or dyslipidaemia and self-reported non-adherence
were excluded. The study was approved by the University
of Cape Town research ethics committee.
Clinical and laboratory evaluations
After obtaining informed consent, we instructed the par-
ticipants to undergo an overnight fast and to note the
time of taking the evening dose of lopinavir on the day
proceeding the study day. On the study day, participants
underwent an oral glucose tolerance tests (OGTT).
Blood was drawn at 0 and 120 minutes after ingestion of
75g glucose in 250ml water, into heparinised or sodium
fluoride tubes as appropriate, and kept on ice until cen-
trifugation within 4 hours. Plasma lopinavir concentra-
tions and serum fasting glucose, cholesterol, and
triglyceride concentrations were determined from the 0
minute samples of the OGTT. The morning doses of
ART were given after 2 hour glucose samples were taken.
Lopinavir drug concentrations were analyzed by fully
validated methods using liquid chromatography-tandem
mass spectrometry (LC-MS/MS) on an Applied Biosys-
tems MDS Sciex API 4000 tandem mass spectrometer at
our ISO17025 compliant and accredited analytical labora-
tory as previously described [13]. The assay range was
0.05 to 20 μg/mL. Accuracy ranged from 94 to 103%.
Any samples with lopinavir concentrations below the
limit of quantification (0.05 μg/mL) were fixed to 0.025
μg/mL. Serum glucose and lipid concentrations were
determined by standard methods using the ACE Alera
Clinical Chemistry System (Alfa Wassermann Diagnostic
Technologies, Woerden, Netherlands). Impaired fasting
glucose (IFG) and impaired glucose tolerance (IGT) were
defined according to the American Diabetes Associationcriteria [14]. Hypercholesterolaemia and hypertriglyceri-
daemia were defined according to the NCEP III criteria [15].
We reviewed medical records to determine duration
on antiretroviral therapy, viral load and CD4 counts. Self
reported adherence was determined using a validated 4-
day adherence questionnaire administered by trained
field workers [16]. Basic anthropometric measurements
were measured by a biokineticist.
Pharmacokinetic and statistical analysis
The plasma lopinavir concentrations were obtained from
0 minute of the OGTT. For data points below the limit
of quantification (0.05 μg/mL), the lopinavir concentra-
tions were fixed to 0.025 μg/mL. The associations be-
tween lopinavir concentrations and glucose, triglycerides,
and cholesterol were determined using univariate linear
regression and multivariate analyses. Logistic regression
was used to determine associations between lopinavir




A previous study found a positive correlation (rho) of
0.32 between lopinavir trough levels and triglyceride
levels [10]. When the sample size is 50, the linear regres-
sion test of rho=0 (alpha= 0.050 two-sided) for normally
distributed triglyceride concentrations, will have 80%
power to detect a rho of 0.375.Results
Of 93 participants enrolled for the study, nine were
excluded due to missing anthropometric and metabolic
data or inaccurate dose-sampling time. The baseline
characteristics of the 84 participants included in the ana-
lysis are in Table 1. The majority were women, reflecting
the epidemic seen in our clinical practice. All partici-
pants reported 100% adherence. The prevalence of
hypercholesterolaemia, hypertriglyceridaemia, impaired
fasting glucose, impaired glucose tolerance, and diabetes
were 29%, 29%, 25%, 14% and 4% respectively. The
plasma LPV concentrations are shown in Figure 1. The
median (IQR) time after dose was 13.2 (12.6 to 14.1)
hours. There were ten participants whose lopinavir con-
centrations were below 1 μg/mL (12%). Of these, 4 were
virologically suppressed, 4 had virologic failure, and 2
had missing viral load data. As there was a significant
association between time after dose and lopinavir con-
centrations, the time after dose was included in the
multivariate regression analyses investigating the associ-
ation between lopinavir concentrations and metabolic
parameters. There were no significant associations be-
tween lopinavir concentrations and lipid and glucose
Table 1 Study population characteristics, N=84
Variable Median (IQR)
or n/N(%)
Age (years) 36 (32–42)
Female n/N (%) 72/84 (86)
Race n/N (%)
Black 84/84 (100)
Weight (kg) 69 (60–82)
Body mass index (kg/m2) 26 (23–32)
Waist: hip ratio 0.88 (0.82-0.94)





Blood pressure mmHg 108/72 (102/66-119/77)




Proportion with <400 copies/mL (%)* 64/74 (86)
Duration on lopinavir (months) 19 (9–29)







Fasting cholesterol 4.3 (3.7 to 5.3)
Fasting triglycerides 1.3 (0.9 to 1.8)
Fasting glucose 5.2 (4.7 to 5.7)
2 hour glucose 6.3 (5.4 to 8.1)
* 10 participants had missing current viral load data.
Figure 1 Scatter plot of lopinavir concentrations (μg/mL) and
the time after the last lopinavir dose (hours). The black dots
denote individual lopinavir concentrations plotted against the time
after the last unobserved lopinavir dose (dose to sampling time)
from 84 participants. The regression line shows negative correlation
between the lopinavir concentrations and the dose to sampling
time (Spearman rho (95%CI)= −0.28(−0.47 to −0.06), p-value 0.01).
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adjusting for age, sex, time after dose, and duration on
lopinavir (Table 2). The lack of association between lopi-
navir concentrations and the metabolic parameters per-
sisted when the 10 participants with lopinavir
concentrations below 1 μg/mL (as they were probably
non-adherent) were excluded (data not shown). Sixty
one percent of participants were on zidovudine and di-
danosine combination (Table 1), as recommended by the
South African antiretroviral guidelines at the time. How-
ever, the different NRTI backbone was not associated
with any of the outcomes evaluated. For example, for tri-
glycerides, in the participants of the same age, sex,duration on lopinavir, and with same lopinavir concen-
tration taken at the same time after dose, there was no
significant difference between those who were on zi-
dovudine/didanosine combination compared to other
NRTI combinations [mean difference −0.22(−0.65 to
0.21) mmol/L, p value =0.31]. Similarly, there was no as-
sociation with NRTI backbone and cholesterol if there
all parameters remained the same [mean difference
−0.18(−0.73 to 0.37) mmol/L, p value =0.51]. There was
no association between lopinavir concentrations above
the median (8 μg/mL) and dyslipidaemia or dysglycae-
mia (see Figure 2).
Discussion
To our knowledge, this is the first study to investigate
the association between lopinavir concentrations and
serum glucose concentrations, and the first to investigate
associations between lopinavir concentrations and serum
lipids in a South African population. Despite a high
prevalence of dyslipidaemia (29%) and dysglycaemia (42%)
in 84 black South African HIV-infected adults treated with
ritonavir-boosted lopinavir for a median duration of
19 months, we found no association between plasma lopi-
navir concentrations and lipid or glucose concentrations.
There was also no significant association between the lopi-
navir concentrations above the median, and hypercholes-
terolaemia, hypertriglyceridaemia or dysglycaemia.
We found the median lopinavir concentration was 8
μg/mL, which is higher than reported elsewhere [17,18],
but comparable to the trough concentrations after
observed doses in a study conducted by our group from
the same community [19]. Lopinavir pharmacokinetics
Table 2 Association between lopinavir trough concentrations and lipid and glucose concentrations
Univariate analyses Multivariate analyses
Variable Beta coefficient (95%CI) P value Beta coefficient (95% CI) P value
Total cholesterol −0.04 (−0.07 to 0.00) 0.07 −0.02 (−0.06 to 0.01) 0.21
Triglycerides −0.01 (−0.04 to 0.02) 0.53 −0.00 (−0.03 to 0.02) 0.86
Fasting glucose −0.01 (−0.04 to 0.02) 0.44 −0.00 (−0.03 to 0.02) 0.78
2 hour glucose −0.02 (−0.09 to 0.06) 0.64 0.00 (−0.05 to 0.06) 0.85
Adjusted for time after dose, age, sex and duration on lopinavir. In the multivariate model for 2 hour glucose, time after dose was an independent predictor
[β-coefficient 0.56 (95% CI 0.23 to 0.88), p= 0.001].
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which may affect treatment outcomes. At least part of
this variability may be explained by host genetic factors.
Associations between human genetic variants and lopi-
navir exposure are incompletely understood and need to
be explored.
The lack of an association between lopinavir concen-
trations and lipid or glucose concentrations that we
found can be explained as follows: First, like all prote-
ase inhibitors, lopinavir exerts its antiviral activity
intracellularly, and the plasma and intracellular half-lives
are different [20]. However, the positive correlation
between lopinavir plasma and intracellular concentra-
tions reported at 4 weeks was not sustained at 24
weeks of treatment [20]. More importantly, the mech-
anism of toxicity associated with protease inhibitor
use, including lopinavir, is still poorly understood, but
is thought to be related to interference with some
cellular endogenous processes. For example, lopinavir
binds to lipoprotein receptor related protein (LPR),
impairing hepatic chylomicron uptake and triglycerideFigure 2 Proportion of participants with dyslipidaemia and dysglycae
the median (8μg/mL). The bar graphs show the proportion of participant
dysglycaemia in 42 participants with lopinavir below the median (fine chec
or above the median (course checked bars). There was no association betw
complications. The odds ratios for lopinavir above the median and the com
hypertriglyceridaemia OR (95%CI): 0.56 (0.29 to 1.33); dysglycaemia OR (95clearance by LPR –lipoprotein lipase complex, causing
hyperlipidaemia [21]. In susceptible individuals, the
resulting hyperlipidaemia may induce diabetes [21].
Second, clinical manifestations of LPV/r toxicity are
also influenced by host susceptibility such as age, sex,
weight, race, advanced HIV disease, concomitant ART,
higher baseline triglyceride or cholesterol concentra-
tions, and genetic susceptibility [2,22,23]. Finally, we
hypothesize that the if the association between plasma
lopinavir concentrations and toxicity exists, it exists in
much lower concentrations, as the dose–response
curve is likely to be flat at the concentrations found in
our study. Therefore, the influence of lopinavir plasma
concentrations on lipids at therapeutic doses, is likely
to be small and larger studies are needed to detect the
small differences. Furthermore, recent data suggests
that lopinavir does not impair insulin sensitivity [7,8],
and therefore, the lack of an association between lopi-
navir and glucose concentrations is not surprising.
Our findings are in contrast with findings from a small
study conducted in 19 patients, which reported thatmia categorized by the lopinavir concentration below or above
s (%) who had hypercholesterolaemia, hypertriglyceridaemia and
ked bars) and in 42 participants with lopinavir concentrations equal to,
een the lopinavir concentrations above the median and the metabolic
plications were: hypercholesterolaemia OR (95%CI): 0.49 (0.19 to 1.30);
CI): 0.63 (0.24 to 1.63).
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patients experiencing grade 3 or 4 lipid elevations [11].
A second larger study (n=126) found that patients with
fasting triglyceride concentrations above the median had
higher lopinavir trough concentrations, but no correl-
ation was found between lopinavir and cholesterol con-
centrations [10]. Four other studies reported findings
similar to ours, with no association between lopinavir
and lipid concentrations [12,17,24,25]. The older prote-
ase inhibitor indinavir is known to cause diabetes [5].
However, after 12 months of treatment with lopinavir,
none of the 73 patients included in another study devel-
oped diabetes [6]. Studies in healthy volunteers have
shown that insulin sensitivity wasn’t altered by lopinavir
in healthy HIV negative men [7,8]. However, a single
dose study in healthy volunteers showed that lopinavir
could inhibit glucose uptake acutely [9]. Data regarding
the association between lopinavir concentrations and
glucose metabolism are lacking.
Our study has several limitations. First, it is a cross
sectional study and we therefore cannot compare lipid
or glucose concentrations prior to lopinavir treatment.
Second, patients with known diabetes or dyslipidaemia
were excluded from the study, and it is possible that
lopinavir may have exacerbated a pre-existing metabolic
defect. Third, our sample size is relatively small, how-
ever, it is larger than most of the previous studies that
have investigated this association [11,17,19]. We aimed
to examine 50 participants to detect a correlation of
0.375. Our analyses used simple and multivariate regres-
sion analyses with various predictors, therefore we con-
tinued to slowly recruit eligible participants until the
end of the study. Fourth, we investigated associations
with pre-dose lopinavir concentrations and metabolic
parameters. The pharmacokinetic parameters area under
the curve or average steady state would be a better
measure of overall drug exposure. Lastly, the last dose of
lopinavir was not observed. To minimize recall bias, par-
ticipants were requested to record the time of last dose
on the appointment card for the day before pharmacoki-
netic sampling.
In conclusion, we did not find an association between
lopinavir concentrations and lipid and glucose concen-
trations. Larger prospective studies are needed to estab-
lish whether an association exists between lopinavir
concentrations and increasing lipids or glucose metabol-
ism changes.
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